

Press Release

ProStrakan Group plc

ProStrakan announces Torrex Chiesi as partner for Xomolix in Austria and CEE

Galashiels, Scotland, 19 May, 2008 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that it has signed an exclusive licence and supply agreement in Central and Eastern Europe (CEE) and Austria with Torrex Chiesi Pharma GmbH (“Torrex Chiesi”) for the sale of Xomolix.

Xomolix is a branded, injectable drug, indicated for the prevention and treatment of post-operative nausea and vomiting (PONV) in adults and, as a second line, in children. It is also indicated for the prevention of nausea and vomiting induced by morphine derivatives during post-operative patient controlled analgesia (PCA) in adults.

Under the terms of the agreement, ProStrakan will exclusively supply Xomolix to Torrex Chiesi in CEE and Austria for a period of 10 years and will receive an undisclosed royalty rate on sales generated by Torrex Chiesi.

ProStrakan already markets Xomolix (under a variety of brand names) in eight European countries, including France, the Netherlands and Portugal, with sales of £4.2m in 2007. Earlier this year the Company was granted Marketing Authorisations in eight further European countries, including Germany and the UK.

Commenting on the announcement, Wilson Totten, ProStrakan’s Chief Executive, said:

“The outlicensing of our products in parts of the world that are non-core for ProStrakan is an important component of our strategy to fully capitalise on the value of these products. In Torrex Chiesi we have a partner who is well-placed to make Xomolix available for patients right across Central and Eastern Europe and in their home country of Austria.”

Ends

Further enquiries:

ProStrakan

Dr Wilson Totten, Chief Executive
Paul Garvey, Chief Financial Officer
Callum Spreng, Corporate Comms

Tel: +44 (0) 1896 664000

Financial Dynamics

David Yates/Ben Brewerton

Tel: +44 (0) 20 7831 3113

Torrex Chiesi

Wolfgang Harrer, Managing Director

Tel: +43 (1) 407 39 19 14

Notes to Editors:

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries. **www.prostrakan.com**